Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Biocon shares gained 2.6 percent to hit a record h
Biocon Thursday announced the US Food and Drug Adm
eLAJ clinics are technology-enabled,smart clinics
The pharmaceutical industry was expecting some fis
Noting that the Finance Minister has shown fiscal